Moderna CEO says vaccine won't be ready to be distributed widely until the spring
Moderna won't be able to seek emergency use authorization for its COVID-19 vaccine candidate earlier than late November, and the vaccine would likely not be available to the general public prior to March, its CEO says.
Moderna CEO Stéphane Bancel told the Financial Times on Wednesday that the company wouldn't have enough data to seek emergency use authorization from the Food and Drug Administration for its coronavirus vaccine candidate before Nov. 25 at the earliest. He also told the Financial Times that the company wouldn't be able to file for approval to get the vaccine to the entire population until late January at the earliest, meaning that "late [first quarter], early [second quarter]" of 2021 is a "reasonable timeline" for approval.
This, CBS News writes, was both a "setback for Moderna" as well as a "blow to claims by" President Trump that a coronavirus vaccine could be ready prior to Election Day. Trump has repeatedly touted such a possibility, and he contradicted experts in his administration during the first 2020 presidential debate on Tuesday while claiming that "we're weeks away from a vaccine."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But Robert Redfield, director of the Centers for Disease Control and Prevention, told Congress last month that in terms of when a vaccine might be "generally available to the American public so we can begin to take advantage" of it to "get back to our regular life, I think we're probably looking at ... late second quarter, third quarter 2021."
Given the Moderna CEO's comments, the Financial Times writes that the "most realistic hope of a pre-election vaccine" would be from Pfizer, as that company's CEO says it should know whether its vaccine works by the end of October. But The New York Times writes that "the idea that it will be ready in October is far-fetched."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Baltimore bridge disaster: Who is going to pay and how?
Today's Big Question Politicians, legal experts, and the insurance industry are all grappling with the financial fallout of America's worst infrastructure tragedy in years
By Rafi Schwartz, The Week US Published
-
Melting polar ice is messing with global timekeeping
Speed Read Ice loss caused by climate change is slowing the Earth's rotation
By Peter Weber, The Week US Published
-
The Week contest: Stick guitar
Puzzles and Quizzes
By The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published